Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

NCT04585035 is registered in ClinicalTrials.gov with InventisBio Co., Ltd as lead sponsor.

NCT NCT04585035
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04585035 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
Lead sponsor
InventisBio Co., Ltd
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 2, 2020
Completion date
December 31, 2025
Enrollment
180 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

crc, nsclc, solid tumor, adult